XNAS
BFRI
Market cap6mUSD
Jun 03, Last price
0.66USD
1D
16.26%
1Q
-24.49%
IPO
-99.25%
Name
Biofrontera Inc
Chart & Performance
P/E
—
P/S
0.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
524.66%
Rev. gr., 5y
7.34%
Revenues
37m
+9.49%
Net income
-18m
L-11.78%
CFO
-10m
L-58.75%
Earnings
Aug 12, 2025
Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 37,303 9.49% | 34,071 18.82% | 28,674 18.98% | |||
Cost of revenue | 19,944 | 56,648 | 51,055 | |||
Unusual Expense (Income) | ||||||
NOPBT | 17,359 | (22,577) | (22,381) | |||
NOPBT Margin | 46.54% | |||||
Operating Taxes | 22 | 14 | 32 | |||
Tax Rate | 0.13% | |||||
NOPAT | 17,337 | (22,591) | (22,413) | |||
Net income | (17,759) -11.78% | (20,131) 3,045.47% | (640) -98.30% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 7,662 | 4,507 | 9,391 | |||
BB yield | ||||||
| Debt | ||||||
Debt current | 548 | 5,286 | 498 | |||
Long-term debt | 5,198 | 2,299 | 2,194 | |||
Deferred revenue | 2,400 | |||||
Other long-term liabilities | 1,273 | 4,247 | 2,863 | |||
Net debt | (166) | 6,164 | (25,064) | |||
| Cash flow | ||||||
Cash from operating activities | (10,270) | (24,895) | (16,199) | |||
CAPEX | (10) | (5) | (38) | |||
Cash from investing activities | (3) | 619 | (5,156) | |||
Cash from financing activities | 14,835 | 8,411 | 14,021 | |||
FCF | 23,610 | (31,583) | (8,991) | |||
| Balance | ||||||
Cash | 5,912 | 1,421 | 27,756 | |||
Long term investments | ||||||
Excess cash | 4,047 | 26,322 | ||||
Stockholders' equity | (117,400) | (99,648) | (79,491) | |||
Invested Capital | 128,028 | 114,751 | 109,979 | |||
ROIC | 14.28% | |||||
ROCE | 163.33% | |||||
| EV | ||||||
Common stock shares outstanding | 5,516,334 | 1,546 | 21,140 | |||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | 18,179 | (21,513) | (21,209) | |||
EV/EBITDA | ||||||
Interest | 2,106 | 600 | 195 | |||
Interest/NOPBT | 12.13% | |||||